Gå direkt till innehåll
ExCEEd Orphan s.r.o. announces joining Your Pharma Partner in Europe network as of May 1, 2021

Pressmeddelande -

ExCEEd Orphan s.r.o. announces joining Your Pharma Partner in Europe network as of May 1, 2021

ExCEEd Orphan s.r.o. announces joining Your Pharma Partner in Europe network as of May 1, 2021

May 1, 2021

ExCEEd Orphan s.r.o. (www.exceedorphan.com), are a Czech-based full business solution provider for Biotechnology and Pharmaceutical companies who are launching their products in Central & Eastern Europe. They proudly announce joining the exclusive network of Your Pharma Partner in Europe (www.yourpharmapartner.eu) as of May 1st, 2021. This exclusive network was established in 2012 by two founding partner companies FrostPharma AB based in Sweden (www.frostpharma.com  and TwinPharma B.V. based in Netherlands (www.twinpharma.com). With the addition of 14 countries in Central & Eastern Europe covered by ExCEEd Orphan, this network is now able to provide services and deliver innovative treatments to patients in 25 European countries that have a population totaling 180 million. All three partner companies agreed to offer jointly their services to Biotechnology and Pharmaceutical companies looking for partners in Nordics & Baltics, BeNeLux and CEE regions: however, they remain as independent contracting, financing, and business operations. 

Jiri Hermanek, CEO and Founding Partner of ExCEEd Orphan s.r.o comments: “We are very proud to join such an exclusive network covering 40% of the European population! We are looking forward to working in partnership with Frost Pharma AB and TwinPharma B.V. to bring innovative medicines to patients in CEE countries.”

Cecilia Bröms-Thell, CEO of FrostPharma AB comments: “We at FrostPharma welcome ExCEEd Orphan s.r.o. to our joint partnership network! Their expertise and knowledge of marketing and sales in the CEE region will enable us to extend our offerings to additional clients interested to launch their products in this important territory.”

Gert van Alewijk, Founding Partner of TwinPharma B.V. adds: “We at TwinPharma are excited and proud to have ExCEEd Orphan s.r.o. as a new partner in our network. By joining us, we expand our territory to such an extent that we become an even more attractive partner for companies that want to introduce their pharmaceuticals in 25 European countries outside the traditional Big 5.

ExCEEd Orphan s.r.o. was founded in 2018 by 5 rare disease experts from multiple countries. The company is focusing on innovative treatments for rare diseases and has extensive experience in launching innovative medicines in this field.  The portfolio of ExCEEd Orphan s.r.o. includes products in therapeutic areas such as hematology, neurology, immunology, and metabolic diseases.

FrostPharma AB is an entrepreneurial Swedish pharmaceutical company specialized in commercialization of products creating value. Since the start in 2017, FrostPharma has successfully commercialized a broad range of products across multiple disease areas, covering all Nordic countries and beyond. Key to success is the ability to match specific patient- and healthcare needs with relevant products in relation to our extensive in-house commercialization competence.

TwinPharma B.V. was founded in 2006 by two experienced Pharma industry professionals Gert van Alewijk and Bauke Buwalda in Netherlands. With TwinPharma, they want to contribute to improving healthcare by making available medicines that were previously not available in the region. The company is focusing on innovative treatments and is currently active in several disease areas such as immunology, hepatology, organ transplant and urology.

For further information, please refer to:

www.yourpharmapartner.eu

www.exceedorphan.com

www.frostpharma.com

www.twinpharma.com

Ämnen

Kategorier


FrostPharma AB, med säte i Danderyd, Sverige, är specialiserat på introduktion, distribution och marknadsföring av läkemedel i Norden. FrostPharma är ett specialistläkemedelsföretag med fokus på att erbjuda läkemedelsalternativ för barn och vuxna med speciella behov.

Relaterat innehåll

FrostPharma AB

FrostPharma är ett svenskt snabbväxande läkemedelsföretag med fokus på kommersialisering och tillgängliggörandet av värdeskapande specialist och sjukhusläkemedel. FrostPharma signerade sitt första produktavtal 2017, och har sedan dess byggt en läkemedelsportfölj innehållande 35 viktiga produkter. Den expansiva portföljutvecklingen har levererats genom ett intensivt affärsutvecklingsarbete, vilket resulterat i både nya produkträttigheter och utveckling av egna produkter. FrostPharma har idag en etablerad kommersialiseringsplattform för specialistläkemedel över hela Norden, och planerar nu proaktivt för en expansion till ytterligare länder inom EU. FrostPharmas produktportfölj är primärt inriktad på sjukhusanvändning och specialistläkemedel där behandlingar initieras på sjukhus.
FrostPharma har dessutom utvecklat ett separat affärsområde som erbjuder hälso- och sjukvården, laboratorium och läkemedelsindustri klimatsmarta hållbara produkter som alternativ till de petroleumbaserade plastprodukter sjukvården använder idag. Dessa produkter tillverkas i Sverige av biokomposit och bioplast och erbjuder hälso- och sjukvård en signifikant reduktion av klimatpåverkande utsläpp.

FrostPharma AB
Berga Backe, 2
182 53 Danderyd
Sverige